These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33813077)

  • 1. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
    Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
    Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
    Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs as the pivotal regulators of cisplatin resistance in osteosarcoma.
    Moghbeli M
    Pathol Res Pract; 2023 Sep; 249():154743. PubMed ID: 37549518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
    Tsai HC; Huang CY; Su HL; Tang CH
    PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
    Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
    Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ANXA2 and Rac1 negatively regulates autophagy and osteogenic differentiation in osteosarcoma cells to confer CDDP resistance.
    Pan B; Pan Y; Wang S; Bai Y; Hu X; Yang Y; Wu L; Liu J
    Biochem Biophys Res Commun; 2023 Oct; 676():198-206. PubMed ID: 37536195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
    Huang H; Wang L; Li M; Wang X; Zhang L
    World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
    Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
    Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
    Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
    Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
    Huang Z; Huang Y; He H; Ni J
    Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.
    Xie C; Xiang W; Shen H; Shen J
    J Orthop Surg Res; 2021 Dec; 16(1):713. PubMed ID: 34876170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
    He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
    Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells.
    Feng H; Zhang Q; Zhao Y; Zhao L; Shan B
    Aging (Albany NY); 2020 Apr; 12(7):6340-6351. PubMed ID: 32289750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.
    Ferretti VA; León IE
    Curr Treat Options Oncol; 2021 Mar; 22(5):41. PubMed ID: 33745006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.